William Blair Reiterates “Outperform” Rating for Alto Neuroscience (NYSE:ANRO)

Alto Neuroscience (NYSE:ANRO)‘s stock had its “outperform” rating restated by research analysts at William Blair in a research note issued to investors on Friday,RTT News reports. William Blair also issued estimates for Alto Neuroscience’s Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.43) EPS.

Alto Neuroscience Trading Up 0.6 %

ANRO stock opened at $2.71 on Friday. The business has a 50-day simple moving average of $3.63 and a 200 day simple moving average of $6.10. Alto Neuroscience has a 52 week low of $2.58 and a 52 week high of $18.35. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.09. Equities research analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its position in Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after acquiring an additional 3,715 shares during the last quarter. Jane Street Group LLC bought a new position in Alto Neuroscience in the third quarter valued at about $124,000. Wells Fargo & Company MN grew its holdings in shares of Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock worth $46,000 after purchasing an additional 3,139 shares during the last quarter. MetLife Investment Management LLC bought a new stake in shares of Alto Neuroscience during the third quarter worth about $146,000. Finally, Deutsche Bank AG grew its holdings in shares of Alto Neuroscience by 31.3% during the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock worth $64,000 after purchasing an additional 3,629 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.